With the aim of developing NK cell therapy concepts that address malignant diseases beyond CD19-expressing B cell neoplasia, which are still difficult to treat, research on primary CAR-NK cells targeting AML is urgently required. The gene discussed is CD19; the disease is acute myeloid leukemia.